Long-term Follow-up of Patients receiving Intraocular Pressure-lowering Medications as Cataract Surgery Candidates: A Case–control Study

Georgios Bontzos, Michail Agiorgiotakis, Efstathios T Detorakis

ABSTRACT

Aim: In this study, we reviewed demographics and biometric characteristics among patients receiving chronic β-blockers and prostaglandins (PGs) for primary open-angle glaucoma. We compared the age at the time of cataract surgery in different patient groups and in a control group which was not under any medication.

Materials and methods: Retrospective chart review of glaucomatous patients who underwent cataract extraction at the Department of Ophthalmology of the University Hospital of Heraklion, Crete, Greece, between January 1998 and December 2016 was done. Age at cataract surgery, axial length (AL), and preoperative and postoperative best-corrected visual acuities (BCVAs) were recorded. A cohort of patients without glaucoma who were operated for cataract extraction was also evaluated.

Results: In all, 320 patients were reviewed. There were significant results in mean age difference between the beta-antagonist and the PG group [3.05 years, 95% confidence interval (CI) 1.54-4.57] and between the beta-antagonist group with the patients receiving a combined therapy (3.02 years, 95% CI 1.14-4.91). No significant difference was found between the PG and the combination group. All the three treated groups had a significant lower mean age than the control group at the time of cataract surgery.

Conclusion: Based on our study, we concluded that there might be a possible association between chronic treatment with beta-antagonist agents and earlier cataract surgical time in the treated eye.

Clinical significance: Intraocular pressure control is often usually achieved using ophthalmic agents. Their topical and systemic effects should be monitored precisely. Earlier cataract formation might be an important side effect which the physician has to keep in mind before choosing the suitable medication.

Keywords: Aqueous humor, Beta-antagonists, Cataract, Glaucoma, Prostaglandins.


Conflict of interest: None

INTRODUCTION

Cataract is the opacification of the natural crystalline lens and breakdown of the lens protein microarchitecture, which adversely affects the transmission of light onto the retina and degrades optical quality.1,2 Cataract still remains a leading cause of visual impairment and blindness worldwide.3–7 The importance of risk factor identification for cataract development is evident and identifying strategies to prevent or delay cataractogenesis will be an essential part of clinical ophthalmic practice in the near future. Moreover, cataract may be concomitant with other ophthalmic morbidities, also affecting the aging human population, such as glaucoma.

Currently, intraocular pressure (IOP) reduction is the main goal of glaucoma treatment. Initial therapy is typically pharmaceutical, with topical ophthalmic agents8–10 such as PG analogues (e.g., tafluprost), β-adrenergic receptor antagonists (β-blockers e.g., timolol), α-adrenergic receptor agonists (α-agonists; e.g., brimonidine), carbonic anhydrase inhibitors (e.g., brinzolamide), and cholinergic receptor agonists (e.g., pilocarpine).11

The pharmacological mechanism of action of these agents varies. Beta-receptors are expressed throughout the eye, and their antagonists reduce aqueous humor production in the ciliary body by inhibiting synthesis of intracellular cyclic adenosine monophosphate.11 Topical carbonic anhydrase inhibitors reduce aqueous humor production by intervening in the carbonic anhydrase-dependent aqueous formation process.11 Prostaglandins accomplish ocular hypotensive effect by enhancing the uveoscleral outflow when binding to prostaglandin F (FP) receptors. The PGs have a minimal effect on aqueous humor production and episcleral venous pressure. They also modulate outflow facility through the trabecular outflow pathway. There are many supporting studies investigating PG mechanisms in the eye.12–15 Finally, α-agonists have a complex action in the aqueous turnover by intervening in both production and outflow mechanisms.16,17
Therefore, IOP-lowering medications alter the physiological aqueous humor secretion and outflow. Since the lens lacks blood vasculature, it receives all its nourishment from the aqueous humor. Nutrients diffuse in and out through the constant aqueous humor flow. Therefore, it should be reasonable to hypothesize that a disruption in lens homeostasis can eventually lead to cataract development. This study examines the potential association between long term antiglaucomatous drug therapy and cataract formation, with a view to estimate the added risk for cataract development in topical glaucoma medication users.

MATERIALS AND METHODS

Design

This study was designed as a retrospective assessment of patient data from hospital archives. All charts of patients who underwent first cataract surgery between January 1998 and December 2016 at the Department of Ophthalmology of the University Hospital of Heraklion, Crete, Greece, were reviewed and data from the first operated eye for cataract were obtained. Patients gave informed written consent for cataract surgery. All investigations analyzed in this study have been carried out in compliance with the Helsinki Declaration and were approved by our local ethics committee.

Subjects

Patients who had been receiving topical IOP-lowering medication in the operated eye at the time of surgery were included for analysis. Patients were separated into three subgroups according to their medication treatment mechanism:

- Group I: Under monotherapy with a β-blocker (timolol 0.5%),
- Group II: Under monotherapy with a PG (latanoprost 0.005% or bimatoprost 0.03%)
- Group III: Patients receiving combination of these medications (β-blocker + PG).

Inclusion criteria also were as follows: Patient age ≥60 years, primary open-angle glaucoma, and receiving the same medication (β-blocker, PG, or a combination treatment of these two) for at least 5 years before surgery. They were eligible for analysis if they presented with IOP values of <20 mm Hg in all their monitoring examinations before cataract extraction. Patients’ data were excluded from analysis if they had received other IOP-lowering medications like α-agonists or cholinergic receptor agonists at any time, reported with angle-closure glaucoma, congenital and traumatic cataracts, prior history of intraocular surgery, any history of inflammatory ocular disease, ocular infection or severe dry eye, and diabetes mellitus diagnosed for over a year before cataract surgery. These conditions can hasten the development of cataract as reported in multiple studies. Also, patients receiving topical or systemic corticosteroids for more than 30 days for any medical condition were also excluded. Finally, eyes with AL more than 28 mm were not included since AL greater than 30.0 mm has been associated with reduction in cataract age at surgery. Data from all non-glaucomatous patients who had cataract surgery and were age 60+ years at the time of their earliest cataract surgical procedure at the same department and during the same time interval were collected. The same exclusion criteria were followed for that control group.

The age at surgery, AL, as well as preoperative and postoperative (at the 6-month interval) BCVs were recorded. Morphological information of the type and density of cataract (i.e., nuclear, cortical, subcapsular) was also included. In all, 320 patients were included providing a high observed statistical power throughout analysis; observed post hoc power was calculated by using Statistical Package for the Social Sciences (SPSS) version 22 and it was equal to 1.

Statistical Analysis

The SPSS version 22.0 statistical package was used to generate graphs and to perform comparison tests between groups. All tests were two-tailed, and a p-value of 0.05 was determined to represent statistical significance. Normality for each of the four groups was verified by using Shapiro–Wilk test (group I: p = 0.53, group II: p = 0.183, and group III: p = 0.155, and general population group IV: p = 0.749, each one greater than α = 0.05). Applying Levene’s test for homogeneity of variances between groups showed that the variances are unequal (p = 0.0001). As the variances and the sample sizes differ, comparisons among the four groups were done using Welch’s robust test and Games–Howell post hoc test.

RESULTS

The profile of this study is presented in Graph 1 and Table 1.

In total, 320 patients were enrolled; 66 were receiving β-blocker topical medication, 98 were receiving PGs, and 78 were receiving a combined treatment of a β-blocker and a PG, either as two different drugs or as a fixed combination. Furthermore, 78 were nonglaucomatous patients who underwent cataract surgery and were assessed as a control group. Comparisons between different groups, standard deviations, and p-values are mentioned in Table 1.

The mean age when patients underwent first cataract surgery was 74.42 (SD = 5.055), and for each subgroup, the mean age is shown in Table 1.

108
There were statistical significant differences, concerning the age of cataract surgery between groups (β-blockers, PGs, combination, and nonglaucomatous groups; Welch's robust test, \( p \approx 0 \)). For additional analysis between groups, Games–Howell post hoc test was applied. As seen in Table 2, there are significant differences for several comparisons and the \( p \)-value for each comparison is reported in Table 2. Comparing the three groups treated for glaucoma with the control group IV shows that mean differences are statistically significant with a younger mean age in the glaucomatous groups. The mean difference between the control and the β-blocker group is 5.88 (95% CI 3.90-7.86), while the control group and the PG group had a mean difference of 2.82 (95% CI 0.85-4.80). Mean difference between control group and combination group was 2.85 (95% CI 0.59-5.12). Moreover, the mean age difference between β-blockers and PG groups was 3.05 (95% CI 1.54-4.57), and between β-blocker and combination group was 3.02 (95% CI 1.14-4.91), which implies that cataract progression is more rapid in patients treated with β-blockers.

Comparing the mean age of groups treated with PGs and combination treatment revealed no significant difference between the two group means (mean difference 0.03 with 95% CI −1.91-1.84).

**DISCUSSION**

To the best of our knowledge, the association between treatment with antiglaucomatous β-blockers or PGs and the timing of cataract surgery has not been previously examined. Findings from this study imply that long-term antiglaucomatous treatment with specific β-blockers (timolol 0.5%) and PGs (latanoprost 0.005% or bimatoprost 0.03%) may lead to earlier cataract formation, compared with controls. A point of interest is that patients with glaucoma are in constant follow-up examinations. Cataract progression is monitored as a part of their ophthalmic examination allowing earlier

**Table 1:** Age variation of cataract surgery for subgroups, based on treatment medication

<table>
<thead>
<tr>
<th>Variable</th>
<th>( n )</th>
<th>Mean age</th>
<th>Standard Deviation</th>
<th>95% CI for mean Lower bound</th>
<th>Upper bound</th>
<th>Minimum</th>
<th>Maximum</th>
</tr>
</thead>
<tbody>
<tr>
<td>Beta-blocker</td>
<td>66</td>
<td>71.3182</td>
<td>3.35655</td>
<td>70.4930</td>
<td>72.1433</td>
<td>63</td>
<td>79</td>
</tr>
<tr>
<td>PG</td>
<td>98</td>
<td>74.3776</td>
<td>4.08799</td>
<td>73.5580</td>
<td>75.1971</td>
<td>66</td>
<td>84</td>
</tr>
<tr>
<td>Combination</td>
<td>78</td>
<td>74.3462</td>
<td>5.24423</td>
<td>73.1638</td>
<td>75.5285</td>
<td>63</td>
<td>85</td>
</tr>
<tr>
<td>Nonglaucomatous</td>
<td>78</td>
<td>77.2051</td>
<td>5.63007</td>
<td>75.9357</td>
<td>78.4745</td>
<td>63</td>
<td>90</td>
</tr>
<tr>
<td>Total</td>
<td>320</td>
<td>74.4281</td>
<td>5.05529</td>
<td>73.8721</td>
<td>74.9841</td>
<td>63</td>
<td>90</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>(I) Medication</th>
<th>(J) Medication</th>
<th>Mean diff. (I-J)</th>
<th>( p )-value</th>
<th>Lower bound</th>
<th>Upper bound</th>
<th>95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Beta-blocker</td>
<td>PG</td>
<td>-3.05937*</td>
<td>0.000003</td>
<td>-4.5764</td>
<td>-1.5423</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Combination</td>
<td>-3.02797*</td>
<td>0.0000297</td>
<td>-4.9101</td>
<td>-1.1458</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Nonglaucomatous</td>
<td>-5.88695*</td>
<td>0.000001</td>
<td>-7.8643</td>
<td>-3.9096</td>
<td></td>
</tr>
<tr>
<td>PG</td>
<td>Beta-blocker</td>
<td>3.05937*</td>
<td>0.000003</td>
<td>1.5423</td>
<td>4.5764</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Combination</td>
<td>0.03140</td>
<td>0.999970</td>
<td>-1.8487</td>
<td>1.9115</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Nonglaucomatous</td>
<td>-2.82758*</td>
<td>0.001621</td>
<td>-4.8032</td>
<td>-0.8520</td>
<td></td>
</tr>
<tr>
<td>Combination</td>
<td>Beta-blocker</td>
<td>3.02797*</td>
<td>0.0000297</td>
<td>1.1458</td>
<td>4.9101</td>
<td></td>
</tr>
<tr>
<td></td>
<td>PG</td>
<td>-0.03140</td>
<td>0.999970</td>
<td>-1.9115</td>
<td>1.8487</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Nonglaucomatous</td>
<td>-2.85897*</td>
<td>0.006933</td>
<td>-5.1218</td>
<td>-0.5961</td>
<td></td>
</tr>
<tr>
<td>Nonglaucomatous</td>
<td>Beta-blocker</td>
<td>5.88695*</td>
<td>0.000001</td>
<td>3.9096</td>
<td>7.8643</td>
<td></td>
</tr>
<tr>
<td></td>
<td>PG</td>
<td>2.82758</td>
<td>0.001621</td>
<td>0.8520</td>
<td>4.8032</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Combination</td>
<td>2.85897*</td>
<td>0.006933</td>
<td>0.5961</td>
<td>5.1218</td>
<td></td>
</tr>
</tbody>
</table>

*The mean difference is significant at the 0.05 level
Glucoma eye drop therapy would ideally maximize IOP-lowering efficacy and minimize adverse reactions. Several long-term topical and systemic side effects have been reported associated with IOP-lowering topical medications. For example, there are concerns regarding systemic side effects after beta-adrenoreceptor blocking activity in the pulmonary and circulatory system. Topical β-blocker may lower heart rate and blood pressure and may induce asthma and worsen chronic obstructive pulmonary diseases. Some long-term topical and systemic side effects have been associated with development of cystoid macular edema after been administered for ocular hypertension. Other benign side effects associated with PGs include eye pruritus, conjunctival hyperemia, periorbital lipodystrophy, and darkening of the iris, eyelashes, and periocular skin. In previous studies, PGs used as topical IOP-lowering agents have been questioned for their possible effects in crystalline lens changes or hemodynamic alterations at the anterior segment, such as pseudoexfoliation syndrome. The pathomechanism underlying any potential association between antiglaucomatous therapy and cataract formation remains unclear. However, some possible explanations might be speculated; a reduction in aqueous humor production can result in reduced oxygen supplies for lens metabolic needs. Since cataract etiology is not fully understood, shifts in aqueous humor hydrodynamics and its association with cataract development may lead to more insights into the underlying mechanisms of cataract disease.

CONCLUSION

In summary, findings from our analysis add indirect evidence to the hypothesis that chronic topical β-blocker use may increase the risk of cataract formation. In future research, prospective, randomized trials are needed to examine the effect of IOP-lowering medication and cataract formation and progression. Since the pharmacological toxicity of antiglaucomatous medications may be cumulative, it is important to examine the time interval during which the patients are exposed and its potential correlation with cataract development.

CLINICAL SIGNIFICANCE

Our study findings suggest that the risk of developing a cataract should be taken under consideration when accessing a patient on topical antiglaucoma drug. Patients should be carefully evaluated regarding their age and overall health when first administered with an antiglaucomatous agent.

REFERENCES

Long-term Follow-up of Patients receiving IOP-lowering Medications


34. Weissman SS, Asbell PA. Effects of topical timolol (0.5%) and betaxolol (0.5%) on corneal sensitivity. Br J Ophthalmol 1990 Jul;74(7):409-412.


